Incrediwear ACL MCL Arthroscopic Surgery Recovery Study
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Activated Incrediwear Products, Sham Incrediwear Products.
- Who it may be relevant to
- Registry conditions: Arthroscopic Surgical Procedures, Anterior Cruciate Ligament Reconstruction. Basic parameters: 18 years — 65 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Randomized Prospective Study to Evaluate the Incrediwear Products Immediately After ACL or ACL+MCL Arthroscopic Surgery
Overview
The goal of this clinical trial is to assess the benefits of using the Incrediwear knee products after anterior cruciate ligament arthroscopic surgery or anterior cruciate ligament and medial collateral ligament (ACL+MCL) arthroscopic surgery, on the postoperative pain, range of motion and effusion. Participant population includes female or male patients in relative good health, 18 to 65 years old. The investigators will compare participants with Incrediwear and placebo Incrediwear products during the first 6-month postoperative period. The main question it aims to answer are: * Will the Incrediwear products help participants to decrease postoperative pain and swelling? * Will the Incrediwear products help the participants by increasing the range of motion in a shorter amount of time than the placebo group? Participants will be asked to maintain a journal documenting surgical site pain, pain medication type and quantity taken. Researcher will compare 90 participants enrolled in one of six groups, double blinded and randomly assigned, to see if the Incrediwear products assist in controlling postoperative swelling, and increase range of motion in a shorter amount of time. * ACL participants randomly assigned the Incrediwear product, placebo product, or none * ACL+MCL participants randomly assigned the Incrediwear product, placebo product, or none
Detailed description
Researcher will identify patients of the Primary Investigator (PI) who are candidate for the study. Subjects must otherwise be in good health as determined by medical history, physical examination, vital signs, and applicable laboratory tests and receive medical clearance for the procedure by the PI.
Subjects must be able to read and sign an informed consent form indicating understand the purpose of, and the procedures required for the study, and are willing to participate and comply with the study protocol.
This will be a prospective study to evaluate the benefit of the Incrediwear product after ACL repair or ACL+MCL repair via arthroscopic surgery. Subjects who fit the inclusion and exclusion criteria will be reviewed on a subject-by-subject basis at the time of informed consent documentation.
Preoperative and Post-Operative Measurements:
Subjective: Participants rates surgical site pain, on a 0-10 Visual Analogue Scale (VAS) pain scale.
Participants will record pain medication type and quantity taken in a daily pain diary.
Objective: Surgical extremity range of motion, and surgical extremity knee effusion.
Measurements will be taken at; Preop appointment, Postop Day 0, Day 3, Day 7, Day 14, Day 21, Day 30 (1 month), Day 45, Day 60 (2 month), Day 100 (3 month), and Day 180 (6 month).
After the surgery, the participant will be placed in the study provided Incrediwear Leg Sleeve from the ankle to the thigh and the Incrediwear sock. The Participant will wear the products at all times, for a minimum of 23 hours per day, for days 1 through 30.
At day 31, the participant will wear the leg sleeve at night, knee sleeve during the day, and is no longer required to wear the Incrediwear sock, until day 180.
At the 6 month postoperative appointment, the participant will turn in the patient journal.
Interventions
- Other Activated Incrediwear Products
Activated Incrediwear products incorporates semiconductor elements within the fabric that releases negative ions when stimulated by body heat. The negative ions activate cellular vibrations that increase blood flow and circulation. - Other Sham Incrediwear Products
Simple fabric Incrediwear products that do not include the semiconductor elements within the fabric.
Primary outcome measures
- Subjective Patient Pain Experience [Time frame: 180 days]
- Pain Medication Usage [Time frame: 180 days]
- Effusion/swelling Measurements [Time frame: 180 days]
- Range of Motion [Time frame: 180 days]
Eligibility criteria
Inclusion criteria
- Consented to protocol
- Compliant to protocol
- BMI less than 35
- Undergoing ACL or ACL+MCL within 30 days
Exclusion criteria
- Rheumatoid Arthritis
- Poorly controlled diabetes (HgA1c > 7.5)
- Previous blood clots
- BMI greater than 35
- Varicosities on operative leg
- Pain management patient
- Prior knee surgery to the operative / study knee
- Worker's Comp patients
- Pregnancy
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- Randomized
- Model
- Parallel assignment
- Masking
- Triple blind
- Primary purpose
- Supportive care
Study locations
United States · 1 center
- Oklahoma Joint Reconstruction Institute — Oklahoma City
Identifiers
NCT: NCT06240780 · 2023-04